Alzinova
Alzinova AB is a Swedish biopharmaceutical company focused on developing treatments for Alzheimer’s disease. Its core programs are the therapeutic vaccine ALZ-101 and the monoclonal antibody ALZ-201, both built on the company’s proprietary scientific platform.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueALZ-101 is a vaccine candidate designed for the treatment of Alzheimer’s disease.
ALZ-201 is an antibody program intended as a complementary Alzheimer’s treatment.
Internal R&D activities that advance the company’s drug candidates through studies.
Business development activities aimed at licensing candidates to pharma partners.
Customers
Alzinova does not sell commercial medicines today; its direct counterparties are pharmaceutical companies, potential licensing partners, CROs, suppliers, and clinical research collaborators. The end beneficiaries are Alzheimer’s patients, while the economic buyers of the programs are larger drug developers that can fund late-stage trials, registration, and commercialization.
They buy rights to ALZ-101 or ALZ-201 through outlicensing or acquisition because they have the scale to run late-stage development and commercialization.
They provide trial execution, regulatory support, and study operations needed to advance the pipeline.
They produce drug substance and drug product for preclinical and clinical use.
They fund the company through equity and other capital raises that support development work.
Strategy
Alzinova’s strategy is to advance ALZ-101 through clinical proof-of-concept while building partnering optionality with larger pharmaceutical companies. It also continues to develop ALZ-201 as a complementary asset, using clinical and regulatory data to strengthen the platform’s licensing value.
Clinical proof-of-concept is central to validating the lead asset and increasing partnering value.
A larger partner can fund late-stage development, registration, and commercialization.
A second asset can broaden the platform and create additional partnering options.
Geography
Alzinova is headquartered in Sweden and reports in SEK, with operations centered on Swedish corporate and development activities. Its business is international in scope because clinical development, regulatory interactions, and partnering discussions involve global pharma counterparties and trial infrastructure, including references to the U.S., Europe, the U.K., and Saudi Arabia.
Risks
Alzinova’s business depends on clinical success, regulatory acceptance, and the ability to finance long development cycles before any product revenue exists. The main risks are trial failure, partner dependence, manufacturing quality, key-person reliance, and the need for repeated external funding.
- Liquidity and financing dependenceImpact: HighLikelihood: High
The company has no commercial product revenue and relies on external capital to fund R&D and trials.
Exposure - Clinical development failureImpact: HighLikelihood: Medium
ALZ-101 must show acceptable efficacy and safety in later-stage studies to justify continuation and partnering.
Exposure: ALZ-101 Phase II and ALZ-201 development
- Supplier and manufacturer dependenceImpact: MediumLikelihood: Medium
Critical development work is outsourced and quality failures could delay studies or regulatory readiness.
Exposure - Key-person and recruitment riskImpact: MediumLikelihood: Medium
A small organization makes the company sensitive to loss of specialized scientific and regulatory staff.
Exposure
Accounting
Judgemental itemsDrug substance and drug product R&D is capitalized, which shifts expense recognition and affects operating loss timing.
Impact: Reported expenses and balance sheet intangible assets
Trial preparation and regulatory applications create uneven quarterly spending patterns.
Impact: Quarter-to-quarter comparability
Rights issues and LTIP warrants affect share count, dilution, and financing capacity.
Impact: EPS, dilution, and cash runway
The company depends on external funding before commercialization, making liquidity assessment critical.
Impact: Financial statement disclosures and investor interpretation
Similar listed companies
Publicly listed companies with a comparable business focus.
Alpha Cognition Inc.
ACOG · Biological Products, (No Diagnostic Substances)
BioArctic
BIOA-B · Health Care
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for severe neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
Alligator Bioscience
ATORX · Health Care
Alligator Bioscience is a Swedish biotech company focused on developing innovative antibody-based medicines for cancer immunotherapy.
Artiva Biotherapeutics, Inc.
ARTV · Biological Products, (No Diagnostic Substances)
Cognition Therapeutics, Inc
CGTX · Biological Products, (No Diagnostic Substances)
Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on small-molecule therapies for age-related degenerative diseases of the central nervous system and retina.
BioVie Inc
BIVIW · Pharmaceutical Preparations
Last updated: 24/09/2026